These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38654381)

  • 21. Clinical outcomes of childhood Langerhans cell histiocytosis in Taiwan: A single-center, 20-year experience.
    Wang DS; Lu MY; Yang YL; Lin DT; Lin KH; Chang HH; Jou ST
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):594-601. PubMed ID: 32741735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine.
    Rodriguez-Galindo C; Kelly P; Jeng M; Presbury GG; Rieman M; Wang W
    Am J Hematol; 2002 Mar; 69(3):179-84. PubMed ID: 11891804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Langerhans cell histiocytosis of spine: a comparative study of clinical, imaging features, and diagnosis in children, adolescents, and adults.
    Huang WD; Yang XH; Wu ZP; Huang Q; Xiao JR; Yang MS; Zhou ZH; Yan WJ; Song DW; Liu TL; Jia NY
    Spine J; 2013 Sep; 13(9):1108-17. PubMed ID: 23602327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.
    Donadieu J; Larabi IA; Tardieu M; Visser J; Hutter C; Sieni E; Kabbara N; Barkaoui M; Miron J; Chalard F; Milne P; Haroche J; Cohen F; Hélias-Rodzewicz Z; Simon N; Jehanne M; Kolenova A; Pagnier A; Aladjidi N; Schneider P; Plat G; Lutun A; Sonntagbauer A; Lehrnbecher T; Ferster A; Efremova V; Ahlmann M; Blanc L; Nicholson J; Lambilliote A; Boudiaf H; Lissat A; Svojgr K; Bernard F; Elitzur S; Golan M; Evseev D; Maschan M; Idbaih A; Slater O; Minkov M; Taly V; Collin M; Alvarez JC; Emile JF; Héritier S
    J Clin Oncol; 2019 Nov; 37(31):2857-2865. PubMed ID: 31513482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
    Monsereenusorn C; Suwannaying K; Techavichit P; Sathitsamitphong L; Komvilaisak P; Rujkijyanont P; Seksarn P; Charoenkwan P; Pakakasama S
    Int J Hematol; 2022 Apr; 115(4):563-574. PubMed ID: 35099760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of High-risk Langerhans Cell Histiocytosis (LCH) in Egyptian Children, Does Intermediate-dose Methotrexate Improve the Outcome?
    Sedky MS; Hamouda A; Taha H; Zaky I; Hassanain O; El Hemaly A; ElHaddad A
    J Pediatr Hematol Oncol; 2019 Nov; 41(8):635-643. PubMed ID: 30247183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment results of Langerhans cell histiocytosis with LSH II protocol].
    Mottl H; Ganevová M; Radvanská J; Chánová M; Smelhaus V; Kodet R; Mrhalová M; Tichý M
    Cas Lek Cesk; 2005; 144(11):753-5. PubMed ID: 16335702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.
    Wang D; Chen XH; Wei A; Zhou CJ; Zhang X; Ma HH; Lian HY; Zhang L; Zhang Q; Huang XT; Wang CJ; Yang Y; Liu W; Wang TY; Li ZG; Cui L; Zhang R
    Orphanet J Rare Dis; 2022 Apr; 17(1):151. PubMed ID: 35379272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
    Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
    Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective study.
    Duan MH; Han X; Li J; Zhang W; Zhu TN; Han B; Zhuang JL; Wang SJ; Cao XX; Cai HC; Chen M; Yang C; Zhou DB
    Leuk Res; 2016 Mar; 42():43-6. PubMed ID: 26859782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study.
    Héritier S; Barkaoui MA; Miron J; Thomas C; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Jeziorski E; Plat G; Aladjidi N; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Pagnier A; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Gandemer V; Martin-Duverneuil N; Taly V; Hélias-Rodzewicz Z; Emile JF; Hoang-Xuan K; Idbaih A; Donadieu J
    Br J Haematol; 2018 Nov; 183(4):608-617. PubMed ID: 30421536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral manifestations of Langerhans cell histiocytosis with unusual histomorphologic features.
    AbdullGaffar B; Awadhi F
    Ann Diagn Pathol; 2020 Aug; 47():151536. PubMed ID: 32454442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late outcomes in children with Langerhans cell histiocytosis.
    Chow TW; Leung WK; Cheng FWT; Kumta SM; Chu WCW; Lee V; Shing MMK; Li CK
    Arch Dis Child; 2017 Sep; 102(9):830-835. PubMed ID: 28442470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary involvement in children with Langerhans cell histiocytosis.
    Coşkun Ç; Kutluk T; Yalçın B; Oğuz B; Orhan D; Yalçın E; Müngen E; Yaman Bajin İ; Özçelik U; Aydın B; Kurucu N; Varan A; Haliloğlu M
    Turk J Pediatr; 2024 Jul; 66(3):323-331. PubMed ID: 39024603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study.
    Morimoto A; Shioda Y; Kudo K; Kanegane H; Imamura T; Koh K; Kosaka Y; Yuza Y; Nakazawa A; Saito AM; Watanabe T; Nakazawa Y
    Int J Hematol; 2023 Jul; 118(1):107-118. PubMed ID: 36871086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification.
    Gadner H; Grois N; Pötschger U; Minkov M; Aricò M; Braier J; Broadbent V; Donadieu J; Henter JI; McCarter R; Ladisch S;
    Blood; 2008 Mar; 111(5):2556-62. PubMed ID: 18089850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High risk Langerhans cell histiocytosis in children: the role of salvage in improving the outcome. A single center experience.
    Sedky MSM; Hamoda A; Taha H; Zaky I; Hassanain O; ElHaddad A
    Orphanet J Rare Dis; 2024 Jun; 19(1):242. PubMed ID: 38910253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDG PET-CT in pediatric Langerhans cell histiocytosis.
    Jessop S; Crudgington D; London K; Kellie S; Howman-Giles R
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28034. PubMed ID: 31599488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Childhood Langerhans cell histiocytosis: a disease with many faces.
    Leung AKC; Lam JM; Leong KF
    World J Pediatr; 2019 Dec; 15(6):536-545. PubMed ID: 31456157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.